It is tough day for the ALS community. But the fight is not over to get Brainstorm's Nurown stem cell treatment approved by FDA this fall. With a 17 to 1 vote against recommending approval due to lack of proof of efficacy and other questions raised by panel of experts the FDA Adcomm Committee that met 9/27/23 choose not to recommend by wide margin. What are the chances of Nurown being approved by FDA? As is going to come out they have always with some good reasons been AGAINST letting ALS patients receive treatment. Here is article from Biospace https://www.biospace.com/article/fda-adcomm-rejects-brainstorm-s-als-therapy-in-nearly-unanimous-vote/#